Epiregulin is a member of the epidermal growth factor (EGF) family, and has certain characteristics that are dierent from that of EGF, including mitogenic responses and binding to EGF receptor (EGFR). Epiregulin may also have another cell surface receptor and/or induces dierent receptor heterodimerizations for intracellular signaling. We investigated the binding ability of epiregulin to four ErbB family receptors using four human breast carcinoma cell lines that expressed dierent subsets of receptors. Chemical cross-linking experiments showed that [ 125 I]epiregulin directly bound to each of EGFR and ErbB-4 but not to ErbB-2 and ErbB-3. Furthermore, although epiregulin stimulated tyrosine phosphorylation of all four ErbB receptors, the main intracellular signal was mediated by ErbB-4 and/or EGFR. The pattern of activation of ErbB family receptors was dierent from that of other EGF-related ligands. Our ®ndings indicate that ErbB-4 and EGFR are receptors for epiregulin, and suggest that EGFrelated ligands transduce signals for dierent biological responses by the hierarchical mechanism.
Introduction
The ErbB family receptors include epidermal growth factor receptor (EGFR), also called ErbB-1/HER1), ErbB-2 (Neu/HER2), ErbB-3 (HER3), and ErbB-4 (HER4). These four receptors are widely expressed in epithelial, mesenchymal, and neuronal tissues and have been implicated in the progression of certain types of human cancer as well as in development (Ullrich et al., 1984; Slamon et al., 1987; Plowman et al., 1990; Lai and Lemke, 1991; Lemoine et al., 1992; Prigent et al., 1992; reviewed in Hynes and Stern, 1994) . The receptors possess a high degree of sequence homology (40 ± 50%) and have a similar molecular structure consisting of an extracellular ligand binding domain, transmembrane domain, protein tyrosine kinase domain, and a C-terminal autophosphorylation domain (Ullrich et al., 1984; Yamamoto et al., 1986; Kraus et al., 1989; Plowman et al., 1990 Plowman et al., , 1993a .
Several ligands that bind to and stimulate the kinase activity of ErbB receptors have also been reported. These can be subdivided into two main groups based on their direct binding to speci®c receptors and structure organization (Groenen et al., 1994; Lee et al., 1995) . One such group of ligands binds speci®cally to and activates EGFR but does not interact directly with ErbB-2, ErbB-3 or ErbB-4. These include epidermal growth factor (EGF) (Savage et al., 1972) , transforming growth factor-a (TGF-a) (Marquardt et al., 1984) , amphiregulin (AR) (Shoyab et al., 1989) , also known as a schwanoma derived growth factor (Kimura et al., 1990) or keratinocyte autocrine growth factor (Cook et al., 1991) , heparin binding-EGF likegrowth factor (HB-EGF) (Higashiyama et al., 1991) , and betacellulin (Shing et al., 1993) .
TGF-a, AR, or HB-EGF stimulates phosphorylation of ErbB-2 and ErbB-3 and ErbB-4 in an EGFRdependent manner (Beerli and Hynes, 1996; Riese et al., 1996b) . Notably, a recent report shows that BTC activates EGFR and ErbB-4 in the absence of additional ErbB family receptor expression (Riese et al., 1996a) . The other group, neuregulins, is comprised of alternative spliced isoforms from a single gene. The group includes neu dierentiation factor (NDF) (Wen et al., 1992) /heregulin (HRG) (Homes et al., 1992) , acetylcholine receptor-inducing activity (Falls et al., 1993) and glial growth factor (Marchionni et al., 1993) . These ligands do not interact directly with EGFR and ErbB-2 but bind with low anity to ErbB-3 and high anity to ErbB-4 (Plowman et al., 1993b; . Although none of these ligands interact directly with ErbB-2 itself, when ErbB-2 is expressed with other members of ErbB receptor family, transphosphorylation of the receptor is observed through ligand-induced heterodimerization of ErbB-2/ EGFR, ErbB-2/ErbB-3, ErbB-2/ErbB-4 (King et al., 1988; Kokai et al., 1989; Plowman et al., 1993b; Sliwkowski et al., 1994; Beerli et al., 1995; Graus-Porta et al., 1995) . Heterodimers of ErbB-2/ErbB-3 are reported to constitute a high anity binding site for HRG . Regulation of signaling of ErbB receptors is very complex since several EGF family ligands have been reported and transactivation occurs through the formation of ligand-induced receptor dimelization and receptor cross-phosphorylation. This may be re¯ective of the diversity of biological responses of EGF-related ligands.
Epiregulin is a recently isolated member of the EGF family and originally found in the conditioned medium of mouse tumorigenic ®broblast NIH3T3/clneT7 cells established from NIH3T3 cells (Toyoda et al., 1995a) . Epiregulin inhibits the growth of several epithelial tumor cells but stimulates the proliferation of ®broblasts, primary rat hepatocytes and human smooth muscle cells. Puri®ed epiregulin is approximately 5.4 kDa single chain polypeptide composed of 46-amino acid residues. Approximately 24 ± 50% of the amino acid sequence of epiregulin is identical to that of EGF-related growth factors. In the intact animal, the expression of epiregulin transcript is detected during the early stages of embryonic life (Toyoda et al., 1995b) . Furthermore, results from our laboratory have shown that the human epiregulin peptide deduced from cDNA sequence is highly homologous to mouse epiregulin and is biologically active (Toyoda et al., 1997) . Although epiregulin inhibits the binding of [ 125 I]EGF to EGFR on A431 cells more weakly than EGF (Toyoda et al., 1995a) , the direct binding of epiregulin to ErbB receptors has not been analysed. In the present study, we investigated whether the signal transduction by epiregulin is mediated by EGFR alone or other ErbB receptors. Our results showed that recombinant human epiregulin binds to EGFR and ErbB-4, stimulates receptor phosphorylation of distinct subset of EGF receptors. (Filmus et al., 1985) and a moderate level of ErbB-3 protein (Kraus et al., 1987; Alimandi et al., 1995) , but does not express of ErbB-2 (Lupu et al., 1990; Hancock et al., 1991) or ErbB-4 mRNA (Plowman et al., 1993a) . The SK-BR-3 cell line expresses EGFR, ErbB-2 (Kraus et al., 1987) and ErbB-3 (Alimandi et al., 1995) but not ErbB-4 mRNA (Plowman et al., 1993a) . The MDA-MB-453 cell line expresses ErbB-2 (Kraus et al., 1987) , ErbB-3 (Alimandi et al., 1995) and ErbB-4 mRNA (Plowman et al., 1990) , but not EGFR mRNA or protein (Yarden and Weiberg, 1989) . T47D cell line expresses moderate levels of the four ErbB family receptors and NDFinduced phosphorylation of ErbB-4 is detected in these cells Graus-Porta et al., 1995; Beerli and Hynes, 1996) .
Results

Binding
As shown in lane 1 of Figure 1 , when immunoprecipitation was performed with anti-EGFR mAb, a protein of approximately 170 ± 185 kDa and large molecular weight protein complexes (4200 kDa) were observed in all cell lines expressing EGFR including MDA-MB-468, SK-BR-3, and T47D cells. In addition, the immunoprecipitated protein was detected by only anti-EGFR mAb in MDA-MB-468 cells. These results indicate that epiregulin is a ligand for EGFR. On the other hand, bands of about 180 kDa were detected in proteins immunoprecipitated with each of anti-ErbB-2 and anti-ErbB-4 antibodies in MDA-MB-453 and T47D cells (lane 3 and 7, Figure 1c or d), suggesting that ErbB-2 and ErbB-4 are candidate for receptors of epiregulin. However, since the band was not detected in SK-BR-3 cell that express ErbB-2 but not ErbB-4, the bands detected is probably co-precipitated ErbB-4 monomers, due to failure of chemical cross-linking to stably associate with ErbB-2. To con®rm this issue, we performed cross-linking analysis in the presence of increasing concentration of unlabeled epiregulin or HRG-a, that binds speci®cally to ErbB-3 and ErbB-4 (Marchionni et al., 1993; Plowman et al., 1993b) (7) or presence (+) of unlabeled epiregulin (10 mg/ml). Cross-linking was performed as described in Materials and methods. Equal amounts of protein (2 mg) were immunoprecipitated with 2 mg/ml of the indicated four anti-ErbB family receptor antibodies. Immune complexes were resolved by 7.5% SDS ± PAGE gel, and radioactive, crosslinked complexes were detected by Bioimaging analyzer formation of cross-linked complexes. [ 125 I]EGF did not generate any radioactive protein by immunoprecipitation with antibodies for four ErbB receptors in MDA-MB-453 cells (data not shown). These results indicate that the labeled protein observed in anti-ErbB-2 immunoprecipitates is ErbB-4, and strongly suggest that epiregulin is a ligand for ErbB-4. The results also demonstrate that epiregulin does not directly bind to ErbB-2 but induces heterodimerization of ErbB-4/ ErbB-2, as well as HRG Sliwkowski et al., 1994; Beerli et al., 1995; GrausPorta et al., 1995) , and EGFR/ErbB-2/ErbB-4. No radioactive protein could be immunoprecipitated with anti-ErbB-3 antibodies in four breast carcinoma cell lines (Figure 1a ± d, lane 5) .
In order to con®rm a direct interaction between epiregulin and EGFR, ErbB-2, ErbB-3 and ErbB-4, the cross-linking analysis was performed using an anti-EGFR mAb that binds to the extracellular domain of EGFR but does not activate tyrosine kinase of EGFR (Kawamoto et al., 1983) . No protein chemically crosslinked with [ 125 I]epiregulin could be immunoprecipitated by pretreatment with anti-EGFR mAb in SK-BR-3 cells (Figure 3a) . Activation of tyrosine phosphorylation of proteins by epiregulin was also inhibited completely in the presence of anti-EGFR mAb in SK-BR-3 cells (Figure 3c ), indicating that the intracellular signal for epiregulin is directly mediated by EGFR rather than ErbB-2 or ErbB-3 and forms a heterodimerization of EGFR/ErbB-2. Anti-EGFR mAb had no eect on the binding of [ (Figure 4) , suggesting that ErbB-4 is another receptor for epiregulin. The labeled bands observed in anti-ErbB-2 immunoprecipitates also competed with HRG-a in similar experiments shown in Figure 2 but in the presence of 10 mg/ml of anti-EGFR mAb (data not shown). Based on these ®ndings, we concluded that epiregulin binds directly to each of EGFR and ErbB-4 but not to ErbB-2 and ErbB-3. Although no protein cross-linked with [ 125 I]epiregulin was immunoprecipitated with anti-ErbB-3 antibody in four breast carcinoma cell lines in this study, we were able to detect epiregulin-induced phosphorylation of ErbB-3 in a manner that was as eective as that of EGF in SK-BR-3 cells as described below. This is probably due to the transphosphorylation of EGFR/ ErbB-3. Alternatively, this may be due to the high sensitivity of the functional assay (i.e. tyrosine phosphorylation) compared with the structural assay (anity labeling).
Epiregulin induces tyrosine phosphorylation of ErbB receptors
In the next step, we compared the induction of tyrosine phosphorylation of ErbB receptors by human epiregulin with that by EGF and HRG-a in four human breast carcinoma cell lines ( Figure 5 ). The results are summarized in Table 1 . Epiregulin at a concentration of 20 ng/ml was slightly less eective than EGF at phosphorylating EGFR in MDA-MB-468, SK-BR-3 and T47D cells (Figure 5a ), in agreement with previous observations that epiregulin has a weak anity to EGFR. On the other hand, the ability of epiregulin to activate ErbB-2 tyrosine phosphorylation was very weak compared with EGF in SK-BR-3 and T47D cells (Figure 5b ). This is probably due to the ability of epiregulin to heterodimerize and transactivate ErbB-2 through EGFR. Epiregulin and EGF did not clearly stimulate tyrosine phosphorylation of ErbB-2 in MDA-MB-453 cells, in contrast to HRG-a. In addition, epiregulin and EGF were signi®cantly less eective than HRG-a in inducing tyrosine phosphorylation of ErbB-3 in SK-BR-3, MDA-MB-453, and T47D cells (Figure 5c ). Epiregulin-induced tyrosine phosphorylation of ErbB-3 was also con®rmed by immunoprecipitation with anti-phosphotyrosyl mAb and blotted with anti-ErbB-3, but not vice versa. The dierence may be due to the low expression level of ErbB-3 in MDA-MB-468 cells or the immunoprecipitation ability of anti-ErbB-3 antibodies used in the present study. These results indicate that epiregulin induces heterodimerization and transphosphorylation of EGFR/ErbB-3. As expected, we were able to observe a clear activation of tyrosine phosphorylation of ErbB-4 by epiregulin in T47D cells (Figure 5d ). Epiregulin exhibited a marked activity and was as ecient as HRG-a, while EGF had a weak eect. Although the level of induction was 
Discussion
We have previously demonstrated that epiregulin inhibits the binding of [ 125 I]EGF to EGFR on an epidormoid carcinoma A431 cell, suggesting that epiregulin is a ligand for EGFR (Toyoda et al., 1995a) . In this study, we analysed the ability of epiregulin to bind to and stimulate tyrosine phosphorylation of ErbB family members by using four human breast carcinoma cell lines. Our results showed that [ 125 I]epiregulin bound directly to ErbB-4 as well as EGFR, but not to ErbB-2 and ErbB-3. Furthermore, epiregulin activated tyrosine phosphorylation of all four ErbB receptors with an eciency equivalent to that of HRG-a in stimulating ErbB-4 in T47D cells. Thus, our data indicate that EGFR and ErbB-4 are receptors for epiregulin. TGF-a, AR and HB-EGF stimulate tyrosine phosphorylation of ErbB-2, ErbB-3, and ErbB-4 through EGFR (Riese et al., 1996b) . On the other hand, HRG/NDF activates EGFR and ErbB-2 through ErbB-3 and ErbB-4 (reviewed in Carraway and Burden, 1995; Pinkas-Kramarski et al., 1996) . Epiregulin exhibited a pattern of receptor binding and activation that was dierent from these peptides. Recent reports described the ability of BTC to induce tyrosine phosphorylation of all four ErbB receptors and a possible direct binding to ErbB-4 as well as EGFR (Beerli and Hynes, 1996; Riese et al., 1996a) . Although similar receptor binding pro®les were observed, epiregulin is probably dierent from BTC with regard to the magnitude of activation of tyrosine phosphorylation of the four ErbB family receptors. The eects of BTC on tyrosine phosphorylation of EGFR and ErbB-2 in T47D cells are similar to those of EGF and NDF, respectively (Beerli and Hynes, 1996) . On the other hand, epiregulin was signi®cantly less active in phosphorylation of EGFR and ErbB-2 than EGF and HRG-a in T47D cells, respectively. Furthermore, although BTC had a much stronger eect on ErbB-3 phosphorylation than EGF in T47D cells (Beerli and Hynes, 1996) , epiregulin-induced ErbB-3 tyrosine phosphorylation was very weak. These results point to the existence of dierences between epiregulin and BTC in their ability of ErbB receptor heterodimer formation following transactivation of ErbB family receptors.
Based on the present results, we can summarize the potency of epiregulin-induced tyrosine phosphorylation ]epiregulin (50 ng/ml) was then added in the absence or presence of 10 mg/ml of unlabeled epiregulin and incubated for 4 h at 48C. Chemical cross-linking and immunoprecipitation with indicated antibodies (2 mg/ml) were performed as described in Materials and methods. Radiolabeled signals were detected by Bioimaging analyzer after resolving the samples by 7.5% SDS ± PAGE gel. (c) SK-BR-3 cells were labeled with [ 32 P]orthophosphate, and medium containing 20 ng/ml of epiregulin was added in the absence or presence of 10 mg/ml of anti-EGFR mAb or isotype control mAb. After 10 min at 378C, tyrosine phosphorylated proteins were isolated as described in Materials and methods and resolved in 7.5% SDS ± PAGE gel. Radiolabeled proteins were detected with Bioimaging analyzer of ErbB receptors as follows: ErbB-45EGFR4ErbB-24ErbB-3. Epiregulin-induced stimulation of tyrosine phosphorylation of ErbB-2 was weaker than that of EGF in SK-BR-3 and T47D cells, and HRG-a in T47D and MDA-MD-453 cells. NDF-induced heterodimerization of the receptors in cells that ectopically expressed ErbB receptors showed that the interaction between ErbB-3 and ErbB-2 is more extensive than the cross-talk between ErbB-4 and ErbB-2 (Tzahar et al., 1996) . On the other hand, epiregulin bound directly to ErbB-4 but not ErbB-3 in four cell lines examined in the present study. Epiregulin is probably unable to induce the complete formation of ErbB-2/ErbB-3 complex. These dierences between epiregulin and HRG-a are partially responsible for the activation of tyrosine phosphorylation of ErbB-2. In summary, the signi®cantly low potency of epiregulin in transactivating ErbB-2, relative to EGF, HRG-a, and probably BTC, is probably due to the very low anity to EGFR and the absence of a direct binding to ErbB-3. Figure 5 Epiregulin-induced tyrosine phosphorylation of ErbB family receptors. Four cell lines were incubated for 10 min at 378C in the absence or presence of ligands (epiregulin, EGF, or HRG-a, each at 20 ng/ml). The cells were then washed, lysed and equal amount of cell lysates (2 mg) were subjected to immunoprecipitation with the indicated antibodies (2 mg/ml). The immunoprecipitates were resolved by SDS ± PAGE and phosphorylated tyrosine was detected with anti-phosphotyrosine mAb (aPY). A very faint band in anti-ErbB-2 immunoprecipitates of MDA-MB-468 cells was occasionally observed when immunoprecipitation was carried out with anti-ErbB-2 antibody and blotted with anti-phosphotyrosyl mAb, however, the band was not observed vice versa, suggesting that it was probably a nonspeci®c band Tzahar et al. (1996) reported that directional and hierarchical networks of interreceptor interactions of ErbB family receptors determine signal transduction by NDF/HRG and EGF. Although EGF-related ligands can be divided into subgroups based on the receptor binding, their ability for receptor phosphorylation and biological eects in breast carcinoma and BaF3 cells that ectopically expressed one or two ErbB receptors are ligand-speci®c. Epiregulin binds to EGFR and ErbB-4 and seems to transduce the main signals by ErbB-4 and EGFR but not by ErbB-2 and ErbB-3. Recent reports and our results suggest that EGF-related ligands transduce signals for dierent biological responses by the hierarchical mechanism.
SK-BR-3 cells
-
Materials and methods
Materials
Recombinant human EGF was obtained from Upstate Biotechnology, Inc. (Lake Placid, NY). Recombinant heregulin-a (HRG-a) was purchased from R&D (Minneapolis, MN). Recombinant human epiregulin of 46 amino acids was produced by Bacillus brevis (Nakazawa et al., in preparation). The biological activity of puri®ed epiregulin was equal to that of chemically-synthesized mouse epiregulin based on stimulation of DNA synthesis in Balb3T3 A31 cells. Monoclonal antibody directed against EGFR (Ab-3), and anti-phosphotyrosine coupled to agarose were obtained from Oncogene Science (Manhasset, NY). Anti-ErbB-2 (C-18), anti-ErbB-3 (C-17) and antiErbB-4 (C-18) antibodies, and anti-phosphotyrosine (PY20) mAb were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The IgG 1 isotype control mAb MOPC.21 was purchased from Sigma (St Louis, MO).
Cell cultures and cell growth assays
Human breast carcinoma cell lines, MDA-MB-468, MDA-MB-453, SK-BR-3, and T47D cells, were obtained from the American Type Culture Collection (Rockville, MD) and maintained in 1 : 1 mixture of DMEM and Ham F12 (DF medium, GIBCO BRL) containing 10% fetal bovine serum (FBS, GIBCO BRL).
Labeling of recombinant human epiregulin and EGF
Human epiregulin and EGF were radioiodinated using the lactoperoxidase (LPO) method (Marchalonis, 1969) with a slight modi®cation. Brie¯y, epiregulin or EGF (2 nmol in 5 ml of water) and 25 ml of 0.5 M sodium phosphate, pH 7.5, were added to 1 mg/ml of LPO (Boehringer Mannheim, Germany). In the next step, we added 4 ml of 0.03% hydrogen peroxide and 2 mCi of Na 125 I (Carrier-free, 3.7 Gbq/ml, Amersham). The reaction mixture was incubated for 10 min at room temperature and applied onto a Sephadex G-15 column (5650 mm, Pharmacia, LKB) pre-equilibrated with 50 mM sodium phosphate buer (pH 7.5), containing 0.05% bovine serum albumin (BSA). After 5 min, radiolabeled epiregulin or EGF was eluted with the same buer described above and stored with the addition of BSA at a ®nal concentration of 1% at 7708C. (Toyoda et al., 1995a) .
Chemical cross-linking and immunoprecipitation
Cells were seeded at 5610 5 /dish in 90 mm tissue culture dish and cultured for 48 h at 378C. The medium was replaced with serum-free DF medium containing 0.1% BSA and cultured for another 24 h. In the next step, the medium was discarded and the cells were washed twice with an ice cold binding buer (DMEM containing 20 mM HEPES, pH 7.5 and 0.1% BSA), and incubated with 2 ml of a binding buer containing 50 ng/ml of [ 125 I]epiregulin or 50 ng/ml of [ 125 I]EGF for 4 h at 48C in the absence or presence of indicated unlabeled epiregulin, EGF, or HRGa, respectively. Disuccinimidyl suberate (DSS, Pierce) was then added to a ®nal concentration of 0.15 mM and the cells were incubated for another 15 min at room temperature. The reaction was terminated by adding 200 ml of a quenching buer containing 10 mM Tris-HCl, pH 7.5, 200 mM glycine and 2 mM EDTA. The cells were then washed twice with ice cold PBS(7) and solubilized in 2 ml of cold lysis buer (10 mM Tris-HCl, pH 7.6, 1% Triton X-100, 5 mM EDTA, 150 mM NaCl, 30 mM sodium pyrophosphate, 50 mM sodium¯uoride, 100 mM sodium orthovanadate, 1 mM PMSF, 1 mM pepstatin, 1 mM leupeptin, 1 U/ml apro®nin) for 30 min at 48C. The lysates were clari®ed by centrifugation for 30 min at 15 000 r.p.m. For immunoprecipitation experiments, equal amounts of cell lysates were incubated overnight with speci®c antibodies at 48C. Protein G-Sepharose (50% v.v, Pharmacia) was then added with continuous stirring for another 2 h at 48C. Complexes were collected by centrifugation for 5 min at 3000 r.p.m., washed ®ve times with lysis buer, boiled for 5 min in an equal volume of twofold SDS ± PAGE sampler buer, clari®ed by centrifugation and analysed by SDS ± PAGE in 7.5% SDS ± PAGE gel (Daiichi Pure Chemical Co, Tokyo) under reduced conditions. The gels were ®xed for 30 min in 10 ± 30% acetic acid-methanol solution, exposed to Bioimaging plate (Fuji®lm, Inc, Tokyo) for 4 h and the resultant cells were analyzed with a Bioimaging analyzer (Model BAS2000, Fuji®lm, Inc, Tokyo).
Metabolic labeling and immunoprecipitation of tyrosinephosphorylated protein
Experiments were performed as described by Johnson et al. (1993) . Cells prepared as described above were washed twice with phosphate-free DMEM (GIBCO BRL) and labeled for 4 h with 2 ml of phosphate-free DMEM containing 2 mCi of [ 32 P]orthophosphate (Carrier-free, 370 MBq/ml, Amersham) at 378C. At the end of incubation, 5 ml of epiregulin was added to the cells to yield a ®nal concentration of 20 ng/ml and further incubated at 378C. After exactly 10 min, the culture plate was placed on ice, the culture medium was removed and washed twice with ice cold phosphate-free DMEM. The cells were solubilized in lysis buer and immunoprecipitated with 50 ml of anti-phosphotyrosyl mAb-agarose (50% v/v) that was pre-equilibrated with a lysis buer. The resultant pellet was washed ®ve times with a lysis buer, and tyrosine-phosphorylated proteins were eluted with 500 ml of lysis buer containing 10 mM phenylphosphate (Sigma). Finally, 20 ml of the eluate was resolved by SDS ± PAGE and analysed as described.
Western blot analysis
Following stimulation, the culture medium was removed and cells were washed twice with ice-cold PBS(7), solubilized in lysis buer and immunoprecipitated with speci®c antibodies as described above. Immunoprecipitates were subjected to SDS ± PAGE in 7.5% SDS ± PAGE gel, electrotransferred onto ProBlott membrane (Applied Biosystems, Inc, CA). After blocking with 5% BSA in PBS(7) containing 0.05% Tween 20, the ®lters were incubated with speci®c antibodies and proteins were detected by peroxidase-coupled secondary antibodies using the ECL detection system (Amersham).
Abbreviations EGFR, epidermal growth factor receptor; ER, epiregulin; EGF, epidermal growth factor; TGF-a, transforming growth factor-a; BTC, betacellulin; HRG, heregulin; NDF, neu dierentiation factor; mAb, monoclonal antibody; PAGE, polyacrylamide gel electrophoresis.
